Zortix matched this thesis to Biotech ETFs as one way for retail investors to get exposure. Not a recommendation.
Peer momentum beats direct momentum in biotech
The research found that momentum of similar companies (peer momentum) based on clinical trial focus works better than a stock's own price momentum.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.